Notes from the Field: Probable Mucormycosis Among Adult Solid Organ Transplant Recipients at an Acute Care Hospital — Pennsylvania, 2014–2015
Weekly / May 13, 2016 / 65(18);481–482
Shannon A. Novosad, MD1,2; Amber M. Vasquez, MD1,2; Atmaram Nambiar, MD3; Matthew J. Arduino, DrPH2; Erick Christensen, MPH4; Heather Moulton-Meissner, PhD2; M. Shannon Keckler, PhD2,5; Jeffrey Miller, MD6; Joseph F. Perz, DrPH2; Shawn R. Lockhart, PhD7; Tom Chiller, MD7; Carolyn Gould, MD2; Lynne Sehulster, PhD2; Mary E. Brandt, PhD7; J. Todd Weber, MD2; Alison Laufer Halpin, PhD2; Rajal K. Mody, MD7 (View author affiliations)View suggested citation
On September 17, 2015, the Pennsylvania Department of Health (PADOH) notified CDC of a cluster of three potentially health care–associated mucormycete infections that occurred among solid organ transplant recipients during a 12-month period at hospital A. On September 18, hospital B reported that it had identified an additional transplant recipient with mucormycosis. Hospitals A and B are part of the same health care system and are connected by a pedestrian bridge. PADOH requested CDC’s assistance with an on-site investigation, which started on September 22, to identify possible sources of infection and prevent additional infections.
Mucormycosis is a severe, often fatal infection caused by a group of angioinvasive molds. Outbreaks of health care–associated mucormycosis have been identified, most commonly in persons with marked immunosuppression, such as bone marrow and solid organ transplant recipients (1,2). Sources of these outbreaks are difficult to determine given that mucormycetes are ubiquitous environmental organisms. Past outbreaks have been associated with contaminated medical supplies and hospital construction projects (3,4). Performing an Infection Control Risk Assessment (ICRA) before and during construction or renovation projects is an important measure that can reduce the risk for health care–associated mucormycosis (4,5). An ICRA is a multidisciplinary approach used to mitigate environmental sources of microbes and to prevent infectious hazards through use of built environment design, ventilation and infrastructure support, and control measures implemented during construction or renovation (6).
A probable health care–associated case of mucormycosis was defined as identification of a mucormycete by culture or molecular testing in a diagnostic specimen from a person who had a history of solid organ transplantation, and admission to hospital A or B during May 2014–September 2015 for ≥14 days, within the 30 days before diagnosis. The period for cases was expanded beyond the 12-month period of infections to account for exposure time during hospitalization. Suspected cases were similarly defined as identification of a mucormycete in a diagnostic specimen by histopathology only or association with a hospital stay of 7–13 days before diagnosis. No infections were considered confirmed health care–associated cases because of uncertainties regarding the incubation period of mucormycosis (3).
The initial three cases were classified as probable and the fourth case as suspected. All four patients underwent solid organ transplantation during the same admission as their mucormycosis diagnosis and were receiving immunosuppressive medications as well as voriconazole for antifungal prophylaxis. The three probable cases were in patients who were primary heart (two cases) and lung transplant (one case) recipients who underwent transplantation 31–93 days before mucormycosis diagnosis. The suspected case occurred in a patient who had been admitted for a second liver transplant and was taking immunosuppressive medications at home; mucormycosis was diagnosed in this patient 13 days after admission, although signs compatible with invasive fungal infection started earlier in the admission. At least two different mucormycete species were isolated from the four patients. Three of the four patients had died before the arrival of the PADOH/CDC team.
The three patients with probable health care–associated mucormycosis all received care in the same room (room A) of the 20-bed cardiothoracic intensive care unit (CTICU) in hospital A for 14–58 days between their transplantations and mucormycosis diagnoses. Room A was the only negative-pressure isolation room in the CTICU and was adjacent to a door leading to a carpeted hallway and family room. Frequent use of this door by personnel and visitors might have disturbed airflow, allowing dust and mold spores, if present, to enter the room. None of the patients had a clinical indication requiring negative-pressure isolation. The patient with suspected health care–associated mucormycosis did not spend any time in room A of the CTICU or a negative-pressure room.
Before the PADOH/CDC on-site investigation had begun, hospital A had closed and deconstructed the CTICU for renovation. A mucormycete genetically unrelated to the patient isolates was recovered from one air sample from room A that hospital A obtained before the renovation work began. Multiple construction and demolition projects were occurring at or near hospitals A and B during the period when this cluster occurred. However, the hospital system reported performing ICRAs for these projects. No common construction-related exposure shared by the four patients was identified.
Although voriconazole is a commonly used antifungal prophylactic agent among transplant recipients in the United States, it is ineffective against mucormycetes (3). Before the PADOH/CDC investigation, the hospital system changed the antifungal prophylactic agent used for transplant recipients to isavuconazole, a mucormycete-active prophylactic agent.
Hospitals A and B are no longer using negative-pressure rooms to house solid organ transplant patients who are without a clinical indication. Caring for immunosuppressed patients in negative-pressure environments has been previously identified as a risk factor for invasive mold infections, possibly related to the potential to concentrate dust and mold spores in these rooms (7). Negative-pressure rooms are recommended for isolation of patients with a suspected or confirmed airborne infectious disease; this investigation highlights how unnecessary placement of immunocompromised patients in negative-pressure rooms could result in net harm and therefore should be avoided.
Corresponding author: Shannon A. Novosad, Snovosad@cdc.gov, 404-639-4353.
1Epidemic Intelligence Service, CDC; 2Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3Pennsylvania Department of Health; 4University of Utah School of Medicine; 5Laboratory Leadership Service, CDC; 6CDC Career Epidemiology Field Officer assigned to Pennsylvania Department of Health; 7Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC.
- Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50:1091–100. CrossRefexternal icon PubMedexternal icon
- Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010;50:1101–11. CrossRefexternal icon PubMedexternal icon
- Davoudi S, Graviss LS, Kontoyiannis DP. Healthcare-associated outbreaks due to Mucorales and other uncommon fungi. Eur J Clin Invest 2015;45:767–73. CrossRefexternal icon PubMedexternal icon
- Kanamori H, Rutala WA, Sickbert-Bennett EE, Weber DJ. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis 2015;61:433–44. CrossRefexternal icon PubMedexternal icon
- American Society for Healthcare Engineering. Infection control risk assessment matrix of precautions for construction and renovation. Chicago, IL: American Society for Healthcare Engineering; 2009. http://www.ashe.org/resources/tools/pdfs/assessment_icra.pdfpdf iconexternal icon
- Bartley J, Olmstead R. Construction and renovation. In: Carrico R, ed. Association of Professionals in Infection Control and Epidemiology (APIC) text of infection control and epidemiology, 3rd ed. Washington DC: Association of Professionals in Infection Control and Epidemiology (APIC); 2009:106–18.
- Thio CL, Smith D, Merz WG, et al. Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit. Infect Control Hosp Epidemiol 2000;21:18–23. CrossRefexternal icon PubMedexternal icon
Suggested citation for this article: Novosad SA, Vasquez AM, Nambiar A, et al. Notes from the Field. Probable Mucormycosis Among Adult Solid Organ Transplant Recipients at an Acute Care Hospital — Pennsylvania, 2014–2015. MMWR Morb Mortal Wkly Rep 2016;65:481–482. DOI: http://dx.doi.org/10.15585/mmwr.mm6518a5external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.